Research that is free to access for all investors. Companies commission these providers to write research about them.
Brokers who write research on their corporate clients and make it available through our main bundle offering.
Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.
Event in Progress:
Discover the latest content that has just been published on Research Tree
Arkema’s FY guidance looked broadly the same between the Q2 and Q3. The range was however condensed to single figures and the wording was changed a bit. This looks like a guidance revision in our view but was so well done that the management was not questioned about this in the conference call. The Q3 figures were a slight beat to consensus at the profitability level (sales: -3.4%; adjusted EBITDA: +2.7%).
Companies: Arkema (AKE:EPA)Arkema SA (AKE:PAR)
AlphaValue
As expected, Arkema reported lower figures compared with the boom, but margins proved resilient reflecting the high share of the specialty chemicals business. However, Intermediates (earmarked for divestment) did better than expected. Interestingly, unlike some of its peers, Arkema did not warn the market about a guidance cut. The company clocked 50% of its guided FY adjusted EBITDA in the first semester confirming our strong view on the stock.
Despite the consensus-beating Q1 profitability, the management was not overly enthusiastic. Interestingly, the Specialty margin fell by less than that of Intermediates, but both parts of the company faced the same triggers for this development. Sales were missed by -1.2% and consensus on the the adjusted EBITDA was beaten by +12.2%.
We had feared that there would be no decent catalysts in 2023 as the change in CEO might not happen this year. There will however be an Investor Day at the end of September, when the management will roll out its new ambitions for the period beyond 2024. The management is very confident that it can reach its 2024 goals as there is only a minor percentage of sales (9%) remaining to be divested. For us, the challenge will rather be the management’s ability to find the right speciality chemicals
The management fully confirmed the FY guidance despite the fact that it was reached after nine months. In the call the management flagged some uncertainties which overhang the performance in the Q4. As destocking seems to be becoming the common denominator in the chemicals industry, we understand why companies are opting for caution. Sales (+6.2%) and adjusted EBITDA (+4.4%) were a clear beat to consensus. The FY consensus currently stands at €2,093m very close to the company’s guidance.
Arkema is now much more fun to cover after a long period of high cyclicality and poor results. For the moment all this is behind us and the management is currently basking in the results of all its hard work. Thing could change rapidly however. Q2 was another consensus-beating quarter (sales: +22.9%; EBITDA: +16.0%), giving the management enough headroom to again raise its guidance after the most recent upgrade in Q1.
Arkema is ‘sailing’ ahead of the cost curve. In our view, this was the main reason for the management to raise the bar. In the call, the management shed some light on the Q2, expecting strong growth at EBITDA level. We are struggling a bit with the low consensus as the beat was substantial (+7.7% to sales, +42.6% to adjusted EBITDA and +52.2% to adjusted EPS). Other companies would have released preliminary figures.
The headline does not imply that Arkema is taking a nap, but another record race should not be expected and the step up is an inorganic one. The 2021 figures were a beat to consensus (sales: +4.2%; adjusted EBITDA: +6.0%). Against the background of the war in Ukraine, we became less optimistic than management.
Arkema was in a position to implement (strong) price increases even in businesses where the company had a ‘tradition’ of suffering from higher raw material prices. We believe availability was also a strong argument. Interestingly, Adhesive Solutions did not benefit as strongly as the other divisions. Q3 figures were above our cautious expectations and beat consensus expectations by +16.4% (top line) and +13.9% (EBITDA).
… to become a speciality chemicals company by 2024, by acquiring something pharma-like. Basically, Arkema plans to acquire the US-based adhesive platforms corralled together at Ashland’s Performance Adhesives business. The charm of the acquisition is that the acquired technologies will be globally rolled out, giving Arkema’s portfolio a broader stance. Management is quite optimistic it can generate substantial synergies including some positive tax effects, which should make the high valuation a
Arkema surfs the chemicals wave well, being carried along by the strong recovery. Supply availability is one side of the coin. On the other, stands cash collection and the company was good at this. Business-wise, the paved path seems to be a well-chosen one. We appreciate the guidance increase, but do not understand that it is based on an unchanged scope after the closing the PMMA divestment. Consensus was beaten by +5.7% (top line) and +21% (adjusted EBITDA).
The top line has already matched the Q1 19 level, but profitability could not fully catch up, despite the optimised business structure, which might be related to the strongly rising raw material prices. Additionally, management managed the organic momentum of the growth well as NWC outflow remained quite stable. Management has become more optimistic after the clear beat in its Q1 guidance. Figures were slightly above our expectations and beat street estimates.
Arkema’s increasing footprint in speciality chemicals helped to protect profitability. Furthermore, management has taken the next steps towards the mid-term target, even in a crisis. By divesting PMMA, its has taken advantage of a special situation, allowing for a decent valuation. Unfortunately, the company still fully consolidates the to-be-divested business showing up our estimates. Consensus was clearly beaten as it still included the PMMA business.
Like other chemicals companies, Arkema had to manoeuvre in challenging times, but the adhesives business was an anchor with its quite resilient business. The other divisions were in rough seas, as expected, giving a mixed picture from a variety of impacts. Intermediates was negatively affected by all factors. The newly-provided guidance looks like a strong commitment. The Q3 figures were a notch stronger than expected, but matched well with the street’s expectations.
Companies: Arkema SA
Like other chemicals, Arkema could not escape from the developments in the customer markets. Nevertheless, the speciality side of the company did quite well despite some meaningful declines in volumes, whereas Intermediates was hit by lower volumes and lower prices. All divisions saw a strong drop in profitability. The divestment proceeds of Functional Polyolefines were a tonic and helped profitability to beat our expectations. Consensus was also beaten.
Research Tree provides access to ongoing research coverage, media content and regulatory news on Arkema SA. We currently have 0 research reports from 3 professional analysts.
Supreme’s FY24 trading update confirms a record performance in the 12 months to 31 March 2024. Organic revenue and profit growth across all four divisions has driven Group revenue +45% YOY to £225m, with FY24 adj. EBITDA almost doubling to ‘at least £38m’, driving record levels of cash generation. Supreme is actively exploring complementary M&A, supported by a debt free balance sheet. Trading on an undemanding FY25 PE of just 6.7x, with a 3.4% yield, we believe downside risks are more than price
Companies: Supreme PLC
Zeus Capital
Companies: FOG PHC FEN BBSN ELIX
Cavendish
Companies: MPE TRI VNET BVXP HVO
Shore Capital
Vianet has published a positive trading update for FY24 with turnover up 7.6% to £15.18m, a 3.5 percentage point increase in gross margin YoY, and adjusted EBITA ahead of market expectations. Net debt continues to fall and closed FY24 at £1.52m (£2.1m at 30 September 2023), demonstrating strong free cash flow generation, even without the benefit of the £0.9m tax receipt received in 1H24, which augers well for a final dividend. The company reported a new contract with Wilcomatic Wash Systems, the
Companies: Vianet Group plc
Capital Access Group
Renewi’s FY24 trading update was in line with management’s expectations and its improved cash generation is reassuring for investors. Attention is now likely to turn the strategic review of the UK Municipals with management stating that they remain on track to update markets by the end of June. This could lead to an exit of key liabilities and leave Renewi as an attractive circular economy investment with strong market positions and organic growth plans, which should assist in generating value,
Companies: Renewi Plc
Edison
Vianet’s FY24 trading update shows FY24 revenue +1% ahead of our previous forecast, adjusted EBITA +2% ahead, EFCF and net debt +£0.6m ahead, and a strategic new customer win with prominent forecourt operator Wilcomatic. A robust FY25 pipeline and outlook leads us to reiterate our FY25E forecasts at this point, with the update highlighting: strong progress renewing and winning new customers on 3-5 year contracts as they migrate from 3G to Vianet’s advanced 4G LTE solutions; the successful integr
Companies: James Latham Plc
SP Angel
Headlam Group has laid out an ambitious long-term revenue target of between £900m and £1bn, as it seeks to grow its share of the UK floor coverings distributor market. Despite a challenging backdrop due to the low level of residential housing transactions, management is seeking to expand each of its sales channels: Trade Counters, Larger Customers, Regional Distribution and Europe & Other. The FY23 results reflected the more challenging environment and the group trades at a discount to its long-
Companies: Headlam Group plc
Norcros has announced the sale of its Johnson Tiles UK business to the current management team for a consideration of £1.0m, with a further modest earnout based on the equity value of the business, both payable in April 2028.
Companies: Norcros plc
The focus of Hardman & Co Research is on the nine quoted Infrastructure Investment Companies (IICs) and on the 22 Renewable Energy Infrastructure Funds (REIFs): the stocks analysed are all members of the Association of Investment Companies (AIC). We are updating our publication of January 2023, assessing both the lacklustre share price performances during 2023 and the key issues, including interest rates, inflation and power prices. As a 31-strong group, its combined market capitalisation is no
Companies: AEIT ROOF DGI9 INPP GSF SEIT USFP HICL ORIT BSIF TRIG NESF SEQI HEIT GRP GCP FSFL 3IN AERI PINT RNEW BBGI GSEO DORE TENT GRID CORD HGEN AEET
Hardman & Co
Companies: CLA STM GLN FXPO KAV GWMO CEY BHP THX EEE
Norcros’s disposal of Johnson Tiles is the latest strategic activity taken by management to better allocate capital to fit with priorities. Last year it closed its UK adhesives operation. Norcros has a compelling investment case, where its new product development initiatives, market positioning and self-help initiatives allow it to take market share in both the UK and South Africa. Its rating is low at 6.0x FY24e P/E, which is attractive, especially when compared to its yield of 5.4% on its well
24th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radi
Companies: FTC AGL SRT SOU G4M AOM SUP
Hybridan
Companies: Ilika plc
Liberum
Share: